Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

NCT03013946 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

121

Enrollment

OTHER

Sponsor class

Stopped insufficient accrual rate

Conditions

Renal Cell Carcinoma, Metastatic
Renal Cell Cancer, Recurrent

Interventions

BEHAVIORAL: Concomitant coaching

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]